[Necessity of novel single-antipsychotic-agent therapies for acute phase of schizophrenia].
Tsutsumi
Yuichiro
Y
D000210:Acute-Phase Reaction / Q000188:drug therapy* / Q000209:etiology; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001569:Benzodiazepines / Q000008:administration & dosage; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists / Q000008:administration & dosage*; D004304:Dosage Forms; D004359:Drug Therapy, Combination; D006801:Humans; D010349:Patient Compliance; D010353:Patient Education as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D014635:Valproic Acid / Q000008:administration & dosage
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D004304:Dosage Forms; D012702:Serotonin Antagonists; D001569:Benzodiazepines; D014635:Valproic Acid; D004298:Dopamine